2 results
Approved WMORecruiting
Primary Objective:* To investigate the value of the Softscan in the early prediction of tumor response (RECIST criteria) to neoadjuvant chemotherapy or hormonal therapy in breast cancer. Secondary Objective:* To assess the accuracy of the Softscan…
Approved WMORecruiting
Primary: • Demonstrate superior efficacy (increased progression-free survival [PFS]) of MEK162 vs. physician*s choice of selected chemotherapies (liposomal doxorubicin, paclitaxel and topotecan)Key Secondary: • Demonstrate superior efficacy (…